Kymera Therapeutics (KYMR) Misses Q3 EPS by 18c

Kymera Therapeutics (NASDAQ: KYMR) reported Q3 EPS of ($0.94), $0.18 worse than the analyst estimate of ($0.76).

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Tesla readies August launch of CyberCab - The Information
• BWS Financial Downgrades Inter Parfums (IPAR) to Sell
• Anthropic revenue run rate surpasses $65 billion ahead of IPO - Bloomberg